Bu Rixin, a partner of Chuangdao Investment Consulting, said in an interview with the science and technology innovation board Journal that the 10 billion M&A fund is mainly aimed at the "integrated circuit design industry", which may be related to the end of the IPO dividend period of chip design companies.The science and technology innovation board Journal reporter noted that over the past year, a number of semiconductor companies have indeed terminated the IPO process. For example, Chengdu Ruiyuan Semiconductor Technology Co., Ltd. terminated its IPO nearly 10 months after the meeting. In addition, more than 20 companies in the semiconductor industry also voluntarily withdrew their materials to terminate the IPO after being inspected on the spot.It is worth mentioning that the Action Plan also mentioned that if the "chain owner" enterprises carry out mergers and acquisitions around the key links of the industrial chain through enterprise venture capital (CVC), the establishment of CVC funds will be included in the fast track. At the same time, government investment funds can participate in M&A fund investment through common shares, preferred shares and convertible bonds, and make appropriate profits.
"The government's participation in M&A fund investment does not mean that the government will dominate the M&A business, but encourage market-oriented institutions and chain owners to lead the M&A business through the above-mentioned M&A fund or parent fund support." Bu Rixin believes.Big move! Shanghai's 10 billion integrated circuit design industry M&A fund has come.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
Bu Rixin believes that in the past few years, after the IPO tide of semiconductors, especially chip design companies, the IPO dividend period of chip design companies has basically ended. "Except for some large chip fields that have not been completely replaced, there are listed companies in other sub-fields, and these fields have already experienced serious involution at the level of low-end products. In the follow-up, if enterprises in these fields are encouraged to conduct IPOs, it is equivalent to encouraging disorderly competition in the industry. "The policy is favorable for surprise attack and seize the opportunity to get on the bus > >For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.
Strategy guide
12-13
Strategy guide
12-13
Strategy guide 12-13
Strategy guide